← Back to Search

Device

MR-001 for Stroke (RhaPSody Trial)

N/A
Waitlist Available
Research Sponsored by MedRhythms, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks
Awards & highlights

RhaPSody Trial Summary

This trial aims to evaluate the feasibility of MR-001 to improve walking capacity, quality of life, mood, and cognition for people with chronic stroke.

Who is the study for?
This trial is for adults over 18 who have had a stroke and now face challenges with walking. They must be able to agree to the study rules themselves and follow through with them. The doctor leading the study will decide if they're likely to benefit from using MR-001 at home safely.Check my eligibility
What is being tested?
The trial tests MR-001, a device or therapy aimed at improving walking in people who've had strokes. Participants use it three times a week for eight weeks while researchers look into how easy it is to bring this treatment into regular use and its effects on walking, mood, life quality, and thinking skills.See study design
What are the potential side effects?
Since MR-001 is being tested for feasibility rather than drug safety, specific side effects are not detailed here. However, any potential risks would be related to its use during walking exercises as prescribed.

RhaPSody Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Enhance understanding of the potential clinical and operational needs and opportunities that may be associated with implementation of MR-001 in various treatment settings.
Secondary outcome measures
2 Minute Walk Test (2MWT)
Generalized Anxiety Disorder (GAD-7) Questionnaire
Patient Health Questionnaire (PHQ-8)
+5 more

RhaPSody Trial Design

1Treatment groups
Experimental Treatment
Group I: InterventionExperimental Treatment1 Intervention
Participants will receive MR-001 delivered to their home via mail. Participants will be asked to use the device for 24 sessions, 3 times a week for 8 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MR-001
2019
N/A
~90

Find a Location

Who is running the clinical trial?

MedRhythms, Inc.Lead Sponsor
5 Previous Clinical Trials
402 Total Patients Enrolled
3 Trials studying Stroke
352 Patients Enrolled for Stroke
Sabrina R Taylor, PhDStudy DirectorHead of Clinical Trials

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any current opportunities for participants to join this trial?

"Clinicaltrials.gov reports that this medical trial is not presently seeking participants, having been posted and updated on August 29th 2023. However, 1123 other clinical trials are nonetheless actively recruiting patients at the moment."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Facilitators and Barriers to the Clinical Implementation of MR-001
2023. "Facilitators and Barriers to the Clinical Implementation of MR-001". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06003790.
~19 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top